The effect of CYP3A5 polymorphism on cyclosporine plasma level in Egyptian renal transplant recipients

详细信息    查看全文

• 作者：Bahaa Eldin Mostafa Zayed ; Dina Mehaney
• 关键词：Immunosuppressants ; Renal transplantation ; Pharmacokinetics
• 刊名：Comparative Clinical Pathology
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：24
• 期：4
• 页码：811-815
• 全文大小：162 KB
• 参考文献：Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K (2007) Influence of the CYP3A5 and MDR1 genetic polymorphism on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 64:185-89PubMed Central PubMed View Article
  Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL (2001) Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs 61:1957-016PubMed View Article
  Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, Ali AS et al (2008) Polymorphism of antimalarial drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 30:10-5PubMed View Article
  Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND et al (2007) Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on cyclosporine dose requirements as assessed by C0 or C2 measurements. Clin Transplant 21:252-57PubMed View Article
  Gervasini G, Vizcanio S, Gaisba C, Carrillo JA, Benitez J (2005) Differences in CYP3A5 genotype distribution and combination with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit 27:819-21PubMed View Article
  Haufroid V, Mourad M, van Kerckhove V, Wawrzyniak J, DeMeyer M, Eddour DC, Malaise J et al (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphism on cyclosporine and tacrolimus dose requirement and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-54PubMed View Article
  Haufroid V, Wallemacq P, Van Kerckhove V, Elans L, De Meyer M, Eddour DC (2006) CYP3A5 and ABCB1 polymorphism and tacrolimus pharmacokinetics in renal transplant candidates: guideline from an experimental study. Am J Transplant 6:2706-713PubMed View Article
  Hesselink DA, van Schaik RH, van der Heiden IP et al (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-54PubMed View Article
  Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D et al (2006) Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 33:1093-098PubMed View Article
  Hustert E, Haberl M, Burk O et al (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-79PubMed View Article
  Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S (2004) Functional evaluation of MDR1 (P-glycoprotein) polymorphisms: high speed screening and structure activity relationship analyses. Drug Metab Pharmacokinet 19:1-4PubMed View Article
  King BP, Leathart JB, Mutch E, Williams FM, Daly AK (2003) CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 55:625-29PubMed Central PubMed View Article
  Kreutz R, Zürcher H, Kain S, Martus P, Offermann G, Beige J (2004) The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14:665-71PubMed View Article
  Lahiri DK, Schnabel B (1993) DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 31:321-28PubMed View Article
  Li DY, Teng RC, Zhu HJ, Fang Y (2013) CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther 51:466-74PubMed View Article
  MacPhee IA, Holt DW (2008) A pharmacogenetic strategy for immunosuppressive based on the CYP3A5 genotype. Transplantation 85:163-65PubMed View Article
  Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L (2009) Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc 41:840-42PubMed View Article
  Meng XG, Guo CX, Feng GQ, Zhao YC, Zhou BT, Han JL, Chen X, Shi Y, Shi HY, Yin JY, Peng XD, Pei Q, Zhang W, Wang G, He M, Liu M, Yang JK, Zhou HH (2012) Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China. Acta Pharmacol Sin 33:1563-570PubMed Central PubMed View Article
  Press RR, Ploegger BA, dan Hartingh J, van der Streaten T, van Pelt J, Danhof M, de Fijiter JW, Guchelaar HJ (2009) Explaining variability in tacrolimus pharmacokinetics to optimise early exposure in adult kidney transplant recipients. Ther Drug Monit 31:187-97PubMed View Article
  Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK (2008) Association of MDR1, CYP3A4*18B, and CYP3A5* 3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 64:10
• 作者单位：Bahaa Eldin Mostafa Zayed (1)
  Dina Mehaney (2)
  
  1. Internal Medicine Department, Faculty of ?Medicine, Cairo University, Cairo, Egypt
  2. Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  Hematology
  Oncology
  
• 出版者：Springer London
• ISSN：1618-565X

文摘

Cyclosporine (CsA) and tacrolimus are immunosuppressants used for the prevention of rejection of transplanted organs. The genes encoding cytochrome (CYP) P450 enzymes, CYP3A4, and CYP3A5 are the main ones involved in the pharmacokinetics of calcinurin inhibitors (CNI). Several single nucleotide polymorphisms were identified in these genes such as CYP3A5*3 (6986A>G). The association of the CYP3A5*3/*3 genotype with decreased clearance of its substrates was reported among different ethnic populations. This study aims to evaluate the effect of CYP3A5*3 polymorphism on CsA plasma levels in Egyptian renal transplant patients at the first week and first month of transplantation. A total of 44 renal transplant recipients receiving CsA were genotyped for CYP3A5*3 polymorphism. The C0 and C2 of CsA were measured and their relationships with CYP3A5*3 genotypes were investigated. CYP3A5*3 allele was present in six patients and the CsA level didn’t differ significantly between the CYP3A5*3 the CYP3A5*1 allele carriers at the first week and the first month post transplantation. Large-scale studies with the involvement of multiple genetic markers claimed to affect the CsA pharmacokinetics are highly recommended to elucidate their pharmacogenetic role in renal transplant patients.